CJC-1295 research guide for Madeiro. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Madeiro looking to source CJC-1295, the first thing to know is that this compound moves through online research channels. The core insight for Madeiro researchers: sourcing CJC-1295 comes down completely to vendor quality evaluation, not geography — and the quality verification approach is the same regardless of where you are. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. What follows is a practical research guide built specifically around CJC-1295, covering everything a Madeiro researcher needs before placing a first order.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Madeiro comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Evaluating CJC-1295 vendors begins with the COA: locate the batch-specific certificate prior to buying, not after. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. For Madeiro researchers evaluating unfamiliar vendors: a test quantity before committing to research volumes before committing to research quantities is what experienced peptide researchers consistently do. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order CJC-1295 — ships to Madeiro
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and restricted human research data. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg in 2mL gives a 2.5mg/mL solution — equivalent to 25mcg per unit on an insulin syringe. Bacterial endotoxin contamination is the most serious safety risk specific to research peptides — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. The research literature on CJC-1295 should be reviewed carefully before beginning any research — study methodologies, dosing, and endpoints vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
